Search results for "lcsh:R895-920"

showing 10 items of 31 documents

Imaging features of adrenal masses

2019

Abstract The widespread use of imaging examinations has increased the detection of incidental adrenal lesions, which are mostly benign and non-functioning adenomas. The differentiation of a benign from a malignant adrenal mass can be crucial especially in oncology patients since it would greatly affect treatment and prognosis. In this setting, imaging plays a key role in the detection and characterization of adrenal lesions, with several imaging tools which can be employed by radiologists. A thorough knowledge of the imaging features of adrenal masses is essential to better characterize these lesions, avoiding a misinterpretation of imaging findings, which frequently overlap between benign …

Adenomalcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyAdenomalcsh:R895-920ReviewImaging modalitiesAdrenal massesMagnetic resonance imagingMedicineRadiology Nuclear Medicine and imagingAdrenal imagingAdrenalComputed tomographyNeuroradiologymedicine.diagnostic_testbusiness.industryMagnetic resonance imagingInterventional radiologymedicine.diseaseSettore MED/18 - Chirurgia GeneraleOncology patientsRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessChemical shift imagingInsights into Imaging
researchProduct

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

2020

Abstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid containing bifunctional DATA5m and DOTA chelators relied on UAMC…

Computer. Automationlcsh:Medical physics. Medical radiology. Nuclear medicine540 Chemistry and allied sciencesPREPPharmacology. Therapylcsh:R895-920Gallium-68lcsh:RM1-950610 MedizinFAPDATA5mChemistrylcsh:Therapeutics. PharmacologyDOTA540 Chemie610 Medical sciencesSquaric acidneoplasmsEJNMMI Radiopharmacy and Chemistry
researchProduct

Clinical microbeam radiation therapy with a compact source: specifications of the line-focus X-ray tube

2020

Highlights • Line-focus X-ray tubes are suitable for clinical microbeam radiation therapy (MRT). • A modular high-voltage supply safely enables high electron beam powers. • An electron accelerator was designed to generate an eccentric focal spot. • We simulated a peak-to-valley dose ratio above 20 for single-field MRT. • Microbeam arc therapy spares healthy brain tissue compared to single-field MRT.

Equivalent uniform doselcsh:Medical physics. Medical radiology. Nuclear medicineMaterials scienceCompact radiation sourcelcsh:R895-920Monte Carlo methodElectronlcsh:RC254-282030218 nuclear medicine & medical imaginglaw.inventionCompact Radiation Source ; Equivalent Uniform Dose ; Line-focus X-ray Tube ; Microbeam Arc Therapy ; Microbeam Radiation Therapy ; Modular High-voltage Supply03 medical and health sciences0302 clinical medicineOpticslawRadiology Nuclear Medicine and imagingFocal Spot SizeOriginal Research ArticleLine-focus X-ray tubeRange (particle radiation)Radiationbusiness.industryMicrobeam arc therapyMicrobeamHot cathodeModular high-voltage supplyX-ray tubeequipment and supplieslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030220 oncology & carcinogenesisCathode raybusinessMicrobeam radiation therapyPhysics and Imaging in Radiation Oncology
researchProduct

Whole-body magnetic resonance imaging and FDG-PET/CT for lymphoma staging: Assessment of patient experience

2017

Purpose: To compare patient experience of whole-body MRI and FDG-PET/CT performed for lymphoma staging. Methods: One-hundred-fifteen patients (59 males, 56 females; 53 Hodgkin, 62 non-Hodgkin; mean age: 43.8 years) with lymphoma underwent whole-body MRI and FDG-PET/CT for staging and filled a questionnaire regarding their experience of the examinations using a 4-point Likert scale (1, very good; 4,very bad). Differences were evaluated using Wilcoxon signed-rank test. Patients were asked to express their preference on both techniques. Preferences were compared on the basis of gender, age, and Ann Arbor stage using the chi-square test. A p-value ≤ .05 was considered significant. Results: Most…

Patient experiencelcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyLymphomaWilcoxon signed-rank testlcsh:R895-920Whole body imagingLymphoma staging030218 nuclear medicine & medical imaging03 medical and health sciencesMagnetic resonance imaging0302 clinical medicinePatient experiencemedicineRadiology Nuclear Medicine and imagingStage (cooking)Whole body imagingmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingmedicine.diseaseLymphomaPositron emission tomography030220 oncology & carcinogenesisRadiologyPositron-emission tomographybusinessThe Egyptian Journal of Radiology and Nuclear Medicine
researchProduct

Ra223 in bone metastases with osteolytic activity

2018

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect. This case report is the first document attesting Ra223 deposit in osteolytic metastases opening new opportunity of therapeutic development…

Radium-223lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtyOsteolysislcsh:R895-920Case ReportScintigraphy030218 nuclear medicine & medical imagingradium 22303 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancerosteoblastic bone metastasesmedicineIn patientRadium-223 Dichlorideosteolytic bone metastasesmedicine.diagnostic_testbusiness.industryBone metastasesTherapeutic effectmedicine.disease030220 oncology & carcinogenesisRadiologybusinessmedicine.drugWorld Journal of Nuclear Medicine
researchProduct

Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid

2016

Background Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in bone targeted radionuclide imaging and therapy. Subsequent to positron emission tomography (PET) examinations utilizing 68Ga-labelled analogues, endoradiotheraphy with 177Lu-labelled macrocyclic bisphosphonates may have a great potential in the treatment of painful skeletal metastases. Methods Based on the established pharmaceuticals pamidronate and zoledronate two new DOTA-α-OH-bisphosphonates, DOTAPAM and DOTAZOL(MM1.MZ) were successfully synthesized. The ligands were labe…

lcsh:Medical physics. Medical radiology. Nuclear medicineBiodistributionMaterials sciencelcsh:R895-920Hydroxy bisphosphonatesSingle-photon emission computed tomography01 natural sciences030218 nuclear medicine & medical imagingAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsmedicineDOTAPharmacology (medical)Radiology Nuclear Medicine and imagingZoledronic acidPharmacologymedicine.diagnostic_test010405 organic chemistrybusiness.industryResearchBone metastaseslcsh:RM1-950Pamidronic acid177LuTheranostics68Ga0104 chemical sciencesZoledronic acidPETlcsh:Therapeutics. PharmacologyDOTAchemistryPositron emission tomographyNuclear medicinebusinessEx vivomedicine.drugEJNMMI Radiopharmacy and Chemistry
researchProduct

Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging

2019

Background Pretargeted imaging allows the use of short-lived radionuclides when imaging the accumulation of slow clearing targeting agents such as antibodies. The biotin-(strept)avidin and the bispecific antibody-hapten interactions have been applied in clinical pretargeting studies; unfortunately, these systems led to immunogenic responses in patients. The inverse electron demand Diels-Alder (IEDDA) reaction between a radiolabelled tetrazine (Tz) and a trans-cyclooctene (TCO)-functionalized targeting vector is a promising alternative for clinical pretargeted imaging due to its fast reaction kinetics. This strategy was first applied in nuclear medicine using an 111In-labelled Tz to image TC…

lcsh:Medical physics. Medical radiology. Nuclear medicineBiodistributionlcsh:R895-920Tetrazine010402 general chemistry01 natural sciencesChemical kineticsTetrazinechemistry.chemical_compoundMedicineDOTARadiology Nuclear Medicine and imagingPretargeted imagingInverse electron-demand Diels–Alder reactionAlendronic acidOriginal ResearchPretargetingTrans-cyclooctene (TCO)biologymedicine.diagnostic_test010405 organic chemistrybusiness.industryScandium-44 (44Sc)RadiochemistryBisphosphonates0104 chemical sciences3. Good healthchemistryPositron emission tomographyPositron emission tomography (PET)biology.proteinInverse electron demand Diels-Alder (IEDDA)businessAvidinEJNMMI Research
researchProduct

5th International Symposium on Focused Ultrasound

2016

Introduction Breast fibroadenomata (FAD) are benign lesions which occur in about 10 % of all women. Diagnosis is made by triple assessment (physical examination, imaging and/or histopathology/cytology). For a definitive diagnosis of FAD, the treatment is conservative unless the patient is symptomatic. For symptomatic patients, the lumps can be surgically excised or removed interventionally by vacuum-assisted mammotomy (VAM). Ablative techniques like high-intensity focused ultrasound (HIFU), cryo-ablation and laser ablation have also been used for the treatment of FAD, providing a minimally invasive treatment without scarring or poor cosmesis. This review summarises current trials using mini…

lcsh:Medical physics. Medical radiology. Nuclear medicineFibroadenomataCryo-ablationHigh-intensity focused ultrasoundAblative techniqueslcsh:R895-920ReviewMeeting AbstractsLaser ablationJournal of Therapeutic Ultrasound
researchProduct

Magnetic Resonance Imaging-Guided Focused Ultrasound Surgery for the Treatment of Symptomatic Uterine Fibroids

2017

Uterine fibroids, the most common benign tumor in women of childbearing age, may cause symptoms including pelvic pain, menorrhagia, dysmenorrhea, pressure, urinary symptoms, and infertility. Various approaches are available to treat symptomatic uterine fibroids. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) represents a recently introduced noninvasive safe and effective technique that can be performed without general anesthesia, in an outpatient setting. We review the principles of MRgFUS, describing patient selection criteria for the treatments performed at our center and we present a series of five selected patients with symptomatic uterine fibroids treated with this not y…

lcsh:Medical physics. Medical radiology. Nuclear medicineInfertilitymedicine.medical_specialtyUterine fibroidslcsh:R895-920Case Report030218 nuclear medicine & medical imagingBenign tumor03 medical and health sciences0302 clinical medicineMedicineVolume reductionmedicine.diagnostic_testUrinary symptomsbusiness.industryPelvic painMagnetic resonance imagingGeneral MedicineFocused ultrasound surgerymedicine.diseasefemale genital diseases and pregnancy complicationsSurgery030220 oncology & carcinogenesisRadiologymedicine.symptomMagnetic Resonance Imaging Interventional - Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) - High-Intensity Focused Ultrasound - Ablation Techniques - Uterine Fibroids - Fertility Preservation - Uterus Sparing TreatmentSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessCase Reports in Radiology
researchProduct

Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC

2019

Purpose The widespread use of 68Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner. The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing both cyclic and acyclic character that may allow for facile access to 68Ga-labelled tracers in the clinic. We report the first bifunctional DATA chelator conjugated to [Tyr3]octreotide (TOC), a somatostatin subtype 2 receptor (SST2)-targeting vector for imaging and functional characterisation of SSTR2 expressing tumours. Methods The radiopharmaceutical precursor, DATA…

lcsh:Medical physics. Medical radiology. Nuclear medicineNET540 Chemistry and allied sciencesDOTA-TOC540 Chemielcsh:R895-920Gallium-68PET-CTDATA-TOCMolecular imagingOriginal ResearchSomatostatin receptorEJNMMI Research
researchProduct